Related Experiment Videos
Mucormycosis, a threatening opportunistic mycotic infection
S Van Steenweghen1, J Maertens, M Boogaerts
1Inwendige Geneeskunde, Dienst Hematologie, K.U.Leuven.
Abstract:
Mucormycosis is a rare and invasive mycotic opportunistic infection, occurring mostly in predisposed patients, mainly diabetics and immunocompromised individuals. The evolution of this fungal infection is frequently fatal unless aggressive treatment is started, or predisposing factors are handled. Our first patient was a known diabetic who had ketoacidotic coma at admission, complicated with pulmonary mucormycosis, and needed surgical resection followed by antimycotic therapy. The second patient did not survive his severe aplastic anemia (with neutropenia) and hemochromatosis (treated with desferrioxamine), complicated with a systemic Rhizopus infection, despite treatment with amphotericin B and granulocyte-colony-stimulating factors.
Insights
Mucormycosis, a rare fungal infection, is often fatal in diabetics and immunocompromised patients. Early intervention and managing underlying conditions are crucial for survival.
Area of Science:
- Mycology
- Infectious Diseases
- Critical Care Medicine
Background:
- Mucormycosis is a rare, invasive, and opportunistic fungal infection.
- It primarily affects individuals with predisposing conditions like diabetes and compromised immunity.
- Prompt treatment and management of underlying factors are critical for patient outcomes.
Observation:
- Case 1: A diabetic patient in ketoacidotic coma developed pulmonary mucormycosis, requiring surgical resection and antifungal therapy.
- Case 2: A patient with severe aplastic anemia, neutropenia, and hemochromatosis (treated with desferrioxamine) developed systemic Rhizopus infection.
- Despite treatment with amphotericin B and granulocyte-colony-stimulating factors, the second patient did not survive.
Findings:
- Aggressive treatment, including surgical intervention and antimycotic therapy, can be life-saving in pulmonary mucormycosis.
- Systemic mucormycosis in severely immunocompromised patients, such as those with aplastic anemia and neutropenia, carries a high mortality rate.
- The use of desferrioxamine in hemochromatosis may be associated with an increased risk of mucormycosis.
Implications:
- Highlights the critical need for early diagnosis and management of mucormycosis in at-risk populations.
- Emphasizes the importance of addressing predisposing factors, such as glycemic control and immune status.
- Suggests a potential link between desferrioxamine use and increased susceptibility to mucormycosis, warranting further investigation.